Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukem...
111 West Lemon Avenue
Monrovia, CA 91016
Founded in 1997
Xencor, Inc. Presents at Oppenheimer 27th Annual Healthcare Conference, Mar-22-2017 08:35 AM
Mar 15 17
Xencor, Inc. Presents at Oppenheimer 27th Annual Healthcare Conference, Mar-22-2017 08:35 AM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, New York, United States. Speakers: Bassil I. Dahiyat, Co-Founder, Chief Executive Officer, President and Director.
Bruce L.A. Carter Not to Stand for Re-Election as Chairman and Board Member of Xencor, Inc
Mar 7 17
Xencor Inc. announced that Bruce L.A. Carter, PhD will not stand for re-election to the board of directors at the 2017 Annual Meeting of Stockholders. Dr. Carter currently serves as the company's chairman as well as a member of the board of directors since 2009. In conjunction with the change, the company will continue its ongoing process to recruit additional board members with skill sets complementary to the current board.
Xencor, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016
Feb 28 17
Xencor, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported net loss of $9,065,000 or $0.21 basic and dilutes per share compared to income of $7,757,000 or $0.19 basic and dilutes per share a year ago. Revenues were $6,440,000 against $21,754,000 a year ago. Loss from operations was $10,028,000 against income of $7,438,000 a year ago. Loss before income taxes was $9,225,000 compared to income before income taxes of $7,757,000 a year ago.
For the year, the company reported net income of $23,625,000 or $0.56 dilute per share compared to $17,592,000 or $0.45 basic and dilute per share a year ago. Revenues were $87,520,000 against $27,762,000 a year ago. Income from operations was $22,540,000 against loss of $18,338,000 a year ago. Income before income taxes was $24,616,000 compared to loss before income taxes of $17,592,000 a year ago. Total revenues earned in 2016 were higher than 2015 due to revenue earned from Novartis Collaboration. The income earned for the year ended December 31, 2016 over the loss sustained in 2015 is primarily due to the revenue earned from Novartis collaboration.